PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
13.37%
Cash & equivalents yoy growth below half of AVXL's 60.18%. Michael Burry would question if the firm faces a liquidity squeeze. Check for rising debts or negative cash flow.
No Data
No Data available this quarter, please select a different quarter.
13.37%
Below half of AVXL's 60.18%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
12.78%
Below half of AVXL's 53.82%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-7.38%
Both AVXL and the company show zero PP&E (Net) Growth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.96%
Both AVXL and the company show zero Total Non-Current Assets Growth.
No Data
No Data available this quarter, please select a different quarter.
12.46%
Below half of AVXL's 53.82%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-8.08%
50-75% of AVXL's -13.25%. Bruce Berkowitz notes the company is paying suppliers faster or not stretching terms as competitor does.
2.29%
Higher Short-Term Debt Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
8.08%
Higher Deferred Revenue (Current) Growth compared to AVXL's zero value, indicating better performance.
-2.29%
Higher Other Current Liabilities Growth compared to AVXL's zero value, indicating worse performance.
-6.99%
Above 1.5x AVXL's -3.36%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.38%
Above 1.5x AVXL's -5.18%. Michael Burry sees a strong spike vs. competitor. Check coverage and debt ratios.
No Data
No Data available this quarter, please select a different quarter.
-9.31%
Above 1.5x AVXL's -3.36%. Michael Burry sees a potential leverage warning sign.
10.53%
Above 1.5x AVXL's 4.58%. Michael Burry suspects heavy new equity expansion or dilution.
-2.12%
Below half AVXL's -4.87%. Michael Burry suspects major net losses or high dividends vs. competitor.
-7.96%
Higher AOCI Growth compared to AVXL's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
13.80%
Below half AVXL's 63.73%. Michael Burry sees potential underperformance in building shareholder capital.
12.46%
Below half AVXL's 53.82%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-16.56%
Higher Total Debt Growth compared to AVXL's zero value, indicating worse performance.
-13.63%
Less than half of AVXL's -60.18%. David Dodd sees better deleveraging or stronger cash buildup than competitor.